Silence Therapeutics (SLN)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

525.00p
   
  • Change Today:
    -15.00p
  • 52 Week High: 649.00
  • 52 Week Low: 414.00
  • Currency: UK Pounds
  • Shares Issued: 89.78m
  • Volume: 79,378
  • Market Cap: £471.37m
  • RiskGrade: 177
  • Beta: 0.21

Silence Therapeutics inks collaboration deal with Hansoh Pharmaceutical

By Josh White

Date: Friday 15 Oct 2021

LONDON (ShareCast) - (Sharecast News) - Silence Therapeutics announced a collaboration with Hansoh Pharmaceutical Group on Friday, to develop short interfering ribonucleic acids (siRNAs) for three undisclosed targets, leveraging its proprietary 'mRNAi GOLD' platform.
The AIM-traded firm said that under the terms of the agreement, Hansoh would have the exclusive option to license rights to the first two targets in Greater China, Hong Kong, Macau and Taiwan following the completion of phase 1 studies.

Silence would retain exclusive rights for the two targets in all other territories.

It would also be responsible for all activities up to option exercise, and would retain responsibility for development outside the China region after first phase studies.

Hansoh would also have the exclusive option to license global rights to a third target at the point of investigational new drug (IND) filing.

Silence said Hansoh would be responsible for all development activities post option exercise for the third target.

Hansoh was set to make a $16m upfront payment, with Silence eligible to receive up to $1.3bn in additional development, regulatory and commercial milestones.

Silence would also receive royalties tiered from low double-digit to mid-teens on Hansoh net product sales.

"We believe Hansoh's extensive clinical development and commercialization experience in China make them an ideal partner," said president and chief executive officer Mark Rothera.

"This collaboration is a good example of our hybrid model in action, balancing proprietary and partnered programs to maximize the substantial opportunity of our mRNAi GOLD platform for targeting disease associated genes in the liver.

"The Hansoh partnership enables us to move two new proprietary programs forward subsidized by non-dilutive capital while also gaining access to the second largest pharmaceutical market globally."

At 1201 BST, shares in Silence Therapeutics were up 2.94% at 542.5p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

SLN Market Data

Currency UK Pounds
Share Price 525.00p
Change Today -15.00p
% Change -2.78 %
52 Week High 649.00
52 Week Low 414.00
Volume 79,378
Shares Issued 89.78m
Market Cap £471.37m
Beta 0.21
RiskGrade 177

SLN Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
43.11% below the market average43.11% below the market average43.11% below the market average43.11% below the market average43.11% below the market average
64% below the sector average64% below the sector average64% below the sector average64% below the sector average64% below the sector average
Price Trend
9.95% above the market average9.95% above the market average9.95% above the market average9.95% above the market average9.95% above the market average
4.92% below the sector average4.92% below the sector average4.92% below the sector average4.92% below the sector average4.92% below the sector average
Income Not Available
Growth
24.97% above the market average24.97% above the market average24.97% above the market average24.97% above the market average24.97% above the market average
25.71% above the sector average25.71% above the sector average25.71% above the sector average25.71% above the sector average25.71% above the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 4
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

SLN Dividends

No dividends found

Trades for 29-Nov-2021

Time Volume / Share Price
14:22 6 @ 525.00p
14:22 150 @ 525.00p
14:22 301 @ 525.00p
14:22 35 @ 522.00p
14:22 305 @ 522.00p

Top of Page